SynthesisAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Minimal clinically important difference in Alzheimer's disease: Rapid review.
Synthesis in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 9 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease.The Cochrane database of systematic reviews · 2026Pooled it
- Efficacy and safety ofFrontiers in pharmacology · 2026Pooled it
- Chinese medicine interventions for cerebral small vessel disease-related cognitive impairment: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Comparative efficacy and certainty of evidence of exercise interventions for cognitive outcomes in older adults with mild cognitive impairment: a systematic review and network meta-analysis of randomized controlled trials.Frontiers in aging neuroscience · 2026Pooled it
- The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis.The journal of prevention of Alzheimer's disease · 2025Pooled it
- Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application.Journal of medical Internet research · 2025Pooled it
- Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.The Cochrane database of systematic reviews · 2024Pooled it
- Minimal clinically important difference in Alzheimer's disease: Rapid review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Pooled it
- Efficacy of transcranial magnetic stimulation for mild cognitive impairment: a systematic review and meta-analysis of randomized controlled trials.Frontiers in neurologyPooled it
- Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer's Disease: Evidence from the VIVA-MIND trial.The journal of prevention of Alzheimer's disease · 2026Trial
- HomeCoRe for telerehabilitation in mild or major neurocognitive disorders: a non-inferiority randomized controlled trial.GeroScience · 2026Trial
- Trial
- Multi-domain Online Therapeutic Investigation Of Neurocognition (MOTION) - A randomized comparative-effectiveness study of two remotely delivered mind-body interventions for older adults with cognitive decline.Contemporary clinical trials · 2025Trial
- What have trials targeting amyloid in Alzheimer's told us to date? The conversation the Alzheimer's field isn't having.Journal of neurology · 2026Article
- Amyloid-beta-targeting monoclonal antibodies in early Alzheimer's disease: a cochrane review summary and appraisal for the neurological community.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Public acceptance and expectations for Lecanemab: Insights from a Smallest Worthwhile Difference study.Psychiatry and clinical neurosciences · 2026Article
- Evaluation of increased oxidative stress in the brain of patients with early Alzheimer's disease byJournal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Priorities of people living with Alzheimer's and care partners: What Matters Most?Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Observational
- Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC.The journal of prevention of Alzheimer's disease · 2026Article
- Major Adverse Cognitive Events (MACE-Cog): A New "MACE" Framework for Cognitive Outcomes in Cardiovascular Diseases and Stroke.Circulation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe conducted a rapid systematic review of minimal clinically important differences (MCIDs) for Alzheimer's disease (AD) trial endpoints.
methodsTwo reviewers searched EMBASE, MEDLINE, and PubMed from inception to June 4, 2023.
resultsTen articles were retrieved. For mild cognitive impairment (MCI), a change of +2 to +3 points on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), +1 points on the Clinical Dementia Rating scale sum of boxes (CDR-SB), -5 points on the integrated Alzheimer's Disease Rating Scale (iADRS), or -1 to -2 points on the Mini-Mental State Examination (MMSE) was considered meaningful. For patients with mild AD, a change of +3 on the ADAS-Cog, +2 points on CDR-SB, -9 points on the iADRS, or -2 points on the MMSE was considered meaningful. For patients with moderate to severe AD, a change of +2 points on the CDR-SB or a change of -1.4 to -3 points on the MMSE was considered meaningful.
conclusionThis review identified previously published MCIDs for AD trial endpoints. Input from patients and caregivers will be needed to derive more meaningful endpoints and thresholds. HIGHLIGHTS: This systematic rapid review identified thresholds for minimal clinically important differences (MCIDs) for recently used Alzheimer's disease (AD) trial endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Clinical Dementia Rating scale sum of boxes (CDR-SB), integrated Alzheimer's Disease Rating Scale (iADRS), Mini-Mental State Examination (MMSE). MCIDs were higher for more severe stages of AD. Average treatment effects in recent trials of anti-amyloid disease modifying monoclonal antibodies are lower than previously published MCIDs. In future trials of disease modifying treatments for AD, the proportion of participants in each treatment group that experienced a clinically meaningful decline could be reported. More work is needed to incorporate the values and preferences of patients and care partners in deriving MCIDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.